These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53. Uric acid transport and disease. So A; Thorens B J Clin Invest; 2010 Jun; 120(6):1791-9. PubMed ID: 20516647 [TBL] [Abstract][Full Text] [Related]
54. A quantitative study of the phagocytosis of urate crystals in the synovial fluid of asymptomatic joints of patients with gout. Pascual E; Jovaní V Br J Rheumatol; 1995 Aug; 34(8):724-6. PubMed ID: 7551655 [TBL] [Abstract][Full Text] [Related]
55. Xanthine oxidoreductase and its inhibitors: relevance for gout. Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228 [TBL] [Abstract][Full Text] [Related]
56. Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells. Capsoni F; Ongari AM; Reali E; Catania A Arthritis Res Ther; 2009; 11(5):R151. PubMed ID: 19814819 [TBL] [Abstract][Full Text] [Related]
57. Downregulation of Transcription Factor T-Bet as a Protective Strategy in Monosodium Urate-Induced Gouty Inflammation. Yang QB; He YL; Zhang QB; Mi QS; Zhou JG Front Immunol; 2019; 10():1199. PubMed ID: 31231373 [TBL] [Abstract][Full Text] [Related]
58. NALP3 inflammasome functional polymorphisms and gout susceptibility. Miao ZM; Zhao SH; Yan SL; Li CG; Wang YG; Meng DM; Zhou L; Mi QS Cell Cycle; 2009 Jan; 8(1):27-30. PubMed ID: 19106604 [TBL] [Abstract][Full Text] [Related]